Ушбу ишга иқтибос қилган ишлар

2 та иш

Иш: CRISPR-engineered T cells in patients with refractory cancer

1. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   МақолаCAR-T cell therapy researchJournal of Hematology & Oncology20250 иқтибос

   ABIABI:AkademIndex/openalex/2025.article.000083

2. Epigenetic mechanisms and next-gen editing platforms in hematology: From molecular basis to therapeutic frontiers

   Minzhi Huang, Ahmad Ewadi, Nazli Servatian +6

   Шарҳ мақолаCRISPR and Genetic EngineeringCritical Reviews in Oncology/Hematology20250 иқтибос

   ABIABI:AkademIndex/openalex/2025.review-article.000099